Esperion Therapeutics, Inc. (LON:0IIM)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 604.13M +372.3% |
| Revenue (ttm) | 316.74M +61.1% |
| Net Income | -5.62M |
| EPS | -0.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 23.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56 |
| Open | 3.140 |
| Previous Close | 3.150 |
| Day's Range | 3.135 - 3.150 |
| 52-Week Range | 0.962 - 4.170 |
| Beta | 1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its product... [Read more]
Financial Performance
In 2025, Esperion Therapeutics's revenue was $403.14 million, an increase of 21.31% compared to the previous year's $332.31 million. Losses were -$22.68 million, -56.17% less than in 2024.
Financial numbers in USD Financial StatementsNews
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, auditor ratification, and a stock plan amendment. No shareholder questions were received, and the CEO closed with thanks to stakeholders.
Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study
Esperion (ESPR) announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits…
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperio...
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Stud...
Esperion Therapeutics Quarterly report: Q1 2026
Esperion Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Esperion downgraded to Hold from Buy at Needham
Needham downgraded Esperion (ESPR) to Hold from Buy after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value right. Published first…
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Esperion downgraded to Hold from Buy at Jefferies
Jefferies downgraded Esperion (ESPR) to Hold from Buy with a price target of $3.28, down from $5, after the company announced it will be acquired by Archimed for $3.16 per…
Esperion downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Esperion (ESPR) to Neutral from Overweight with a price target of $3.16, down from $9, after funds managed by Archimed announced a deal to acquire Esperion for…
Esperion downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Esperion (ESPR) to Neutral from Buy with a $3.16 price target after the company agreed to be acquired by investment firm Archimed for for $3.16 per share.
Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Esperion (ESPR) to Neutral from Overweight with a $3.16 price target after funds managed by Archimed announced a deal to acquire Esperion for $3.16 per share in…
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Esperion to be acquired by Archimed for $3.16 per share, one CVR
Esperion (ESPR) and Archimed announced that they have entered into a definitive agreement under which funds managed by Archimed will acquire Esperion in a transaction valued at up to approximately…
Esperion to be Acquired by ARCHIMED
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Esperion to Report First Quarter 2026 Financial Results on May 7
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Proxy statement: Proxy filing
Esperion Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Significant revenue growth and strategic expansion were highlighted, including the acquisition of Corstasis and the upcoming launch of Enbumyst for heart failure. Updated treatment guidelines and international launches are expected to drive further growth, while pipeline advancements and manufacturing improvements support long-term profitability.
Esperion, Athyrium Capital enter $50M royalty financing agreement
Athyrium Capital and Esperion (ESPR) announced the entry into a $50M royalty financing agreement under which certain funds managed by Athyrium Capital Management will acquire 100% of Esperion’s royalt...
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty fi...